RGT
0.072
105.7%
KLV
0.046
-42.5%
TAT
0.03
76.5%
1TT
0.002
-33.3%
8CO
0.04
66.7%
ARV
0.003
-25%
MOM
0.003
50%
EV1
0.009
-25%
X2M
0.006
50%
AUQ
0.034
-24.4%
PGD
0.16
45.5%
IMU
0.105
-22.2%
CTO
0.013
44.4%
NWM
0.007
-22.2%
AXL
0.084
42.4%
RLF
0.035
-20.5%
KTA
0.007
40%
BPG
0.4
-20%
SKN
0.007
40%
CLU
0.012
-20%
PL3
0.12
33.3%
MQR
0.004
-20%
CCX
0.054
31.7%
RGL
0.008
-20%
ARI
0.025
31.6%
CBE
0.265
-19.7%
CXU
0.115
27.8%
NPM
0.017
-19%
DXN
0.21
27.3%
CYP
0.013
-18.8%
SVY
0.019
26.7%
PKY
0.048
-18.6%
MAY
0.005
25%
C1X
0.11
-18.5%
CLG
0.032
23.1%
TKM
0.11
-18.5%
CKA
0.049
22.5%
MI6
0.62
-18.4%
CPN
0.115
22.3%
OD6
0.115
-17.9%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Chimeric Therapeutics (ASX:CHM): Reports first patient enrolled in chm clinical trial

Chimeric Therapeutics (ASX:CHM) has reported that the first participant has been enrolled in the Phase 1/2 multi-center clinical trial for CHM CDH17 cell therapy.

🩺 This therapy targets advanced gastrointestinal cancers like colorectal cancer, gastric cancer, and neuroendocrine tumors.
🏆 The trial aims to find the recommended dose and assess safety and effectiveness.

ASX announcement: https://announcements.asx.com.au/asxpdf/20240722/pdf/065szt55mn24fq.pdf